Eagle Pharmaceuticals (EGRX) Competitors

$0.38 0.00 (0.00%)

As of 05/13/2026

EGRX vs. VTGN, AEON, TXMD, AKAN, and VYNE

Should you buy Eagle Pharmaceuticals stock or one of its competitors? MarketBeat compares Eagle Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Eagle Pharmaceuticals include VistaGen Therapeutics (VTGN), AEON Biopharma (AEON), TherapeuticsMD (TXMD), Akanda (AKAN), and VYNE Therapeutics (VYNE). These companies are all part of the "pharmaceutical products" industry.

How does Eagle Pharmaceuticals compare to VistaGen Therapeutics?

VistaGen Therapeutics (NASDAQ:VTGN) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, media sentiment, dividends, profitability, risk and institutional ownership.

VistaGen Therapeutics has a beta of 0.31, meaning that its share price is 69% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its share price is 17% less volatile than the broader market.

Eagle Pharmaceuticals' return on equity of 0.00% beat VistaGen Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VistaGen Therapeutics	N/A	-109.72%	-89.62%
Eagle Pharmaceuticals	N/A	N/A	N/A

In the previous week, VistaGen Therapeutics had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for VistaGen Therapeutics and 1 mentions for Eagle Pharmaceuticals. VistaGen Therapeutics' average media sentiment score of 0.87 beat Eagle Pharmaceuticals' score of 0.00 indicating that VistaGen Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VistaGen Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eagle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

VistaGen Therapeutics presently has a consensus target price of $0.95, indicating a potential upside of 46.02%. Given VistaGen Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe VistaGen Therapeutics is more favorable than Eagle Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VistaGen Therapeutics	1 Sell rating(s)	4 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.80
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Eagle Pharmaceuticals has higher revenue and earnings than VistaGen Therapeutics. VistaGen Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VistaGen Therapeutics	$490K	52.61	-$51.42M	-$1.89	N/A
Eagle Pharmaceuticals	$257.55M	0.02	$35.64M	$1.18	0.32

78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by company insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Eagle Pharmaceuticals beats VistaGen Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

22.8% of AEON Biopharma shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 9.4% of AEON Biopharma shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

AEON Biopharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

In the previous week, AEON Biopharma had 1 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 2 mentions for AEON Biopharma and 1 mentions for Eagle Pharmaceuticals. AEON Biopharma's average media sentiment score of 0.00 equaled Eagle Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eagle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Eagle Pharmaceuticals	N/A	N/A	N/A

Eagle Pharmaceuticals has higher revenue and earnings than AEON Biopharma. AEON Biopharma is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$2.43	N/A
Eagle Pharmaceuticals	$257.55M	0.02	$35.64M	$1.18	0.32

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Eagle Pharmaceuticals beats AEON Biopharma on 7 of the 12 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to TherapeuticsMD?

TherapeuticsMD (NASDAQ:TXMD) and Eagle Pharmaceuticals (NASDAQ:EGRX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, earnings, media sentiment, profitability, dividends, valuation and institutional ownership.

30.7% of TherapeuticsMD shares are owned by institutional investors. Comparatively, 85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. 1.7% of TherapeuticsMD shares are owned by insiders. Comparatively, 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

TherapeuticsMD has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market. Comparatively, Eagle Pharmaceuticals has a beta of 0.83, meaning that its stock price is 17% less volatile than the broader market.

In the previous week, TherapeuticsMD had 4 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 5 mentions for TherapeuticsMD and 1 mentions for Eagle Pharmaceuticals. TherapeuticsMD's average media sentiment score of 1.17 beat Eagle Pharmaceuticals' score of 0.00 indicating that TherapeuticsMD is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TherapeuticsMD	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Eagle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TherapeuticsMD has a net margin of 5.34% compared to Eagle Pharmaceuticals' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Eagle Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TherapeuticsMD	5.34%	0.32%	0.23%
Eagle Pharmaceuticals	N/A	N/A	N/A

Eagle Pharmaceuticals has higher revenue and earnings than TherapeuticsMD. TherapeuticsMD is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TherapeuticsMD	$3.02M	7.62	-$570K	-$0.01	N/A
Eagle Pharmaceuticals	$257.55M	0.02	$35.64M	$1.18	0.32

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

TherapeuticsMD and Eagle Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to Akanda?

Eagle Pharmaceuticals (NASDAQ:EGRX) and Akanda (NASDAQ:AKAN) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Eagle Pharmaceuticals has higher revenue and earnings than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.02	$35.64M	$1.18	0.32
Akanda	$840K	15.71	-$4.10M	N/A	N/A

Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Akanda has a beta of 14.49, indicating that its share price is 1,349% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 1.0% of Akanda shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 20.4% of Akanda shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Akanda had 5 more articles in the media than Eagle Pharmaceuticals. MarketBeat recorded 6 mentions for Akanda and 1 mentions for Eagle Pharmaceuticals. Akanda's average media sentiment score of 0.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that Akanda is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Eagle Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Akanda	2 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
Akanda	N/A	N/A	N/A

Summary

Akanda beats Eagle Pharmaceuticals on 5 of the 9 factors compared between the two stocks.

How does Eagle Pharmaceuticals compare to VYNE Therapeutics?

Eagle Pharmaceuticals (NASDAQ:EGRX) and VYNE Therapeutics (NASDAQ:VYNE) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, dividends and institutional ownership.

Eagle Pharmaceuticals has higher revenue and earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Eagle Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Eagle Pharmaceuticals	$257.55M	0.02	$35.64M	$1.18	0.32
VYNE Therapeutics	$570K	39.19	-$26.48M	-$0.78	N/A

Eagle Pharmaceuticals has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, VYNE Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Eagle Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75

85.4% of Eagle Pharmaceuticals shares are owned by institutional investors. Comparatively, 83.8% of VYNE Therapeutics shares are owned by institutional investors. 28.9% of Eagle Pharmaceuticals shares are owned by insiders. Comparatively, 3.0% of VYNE Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

In the previous week, Eagle Pharmaceuticals and Eagle Pharmaceuticals both had 1 articles in the media. VYNE Therapeutics' average media sentiment score of 1.89 beat Eagle Pharmaceuticals' score of 0.00 indicating that VYNE Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Eagle Pharmaceuticals	Neutral
VYNE Therapeutics	Very Positive

Eagle Pharmaceuticals has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,646.14%. Eagle Pharmaceuticals' return on equity of 0.00% beat VYNE Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Eagle Pharmaceuticals	N/A	N/A	N/A
VYNE Therapeutics	-4,646.14%	-74.86%	-63.87%

Summary

Eagle Pharmaceuticals beats VYNE Therapeutics on 9 of the 13 factors compared between the two stocks.

Get Eagle Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EGRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EGRX vs. The Competition

Export

Metric	Eagle Pharmaceuticals	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.87M	$935.60M	$6.34B	$12.37B
Dividend Yield	N/A	4.84%	2.80%	5.35%
P/E Ratio	0.32	1.48	20.66	25.63
Price / Sales	0.02	115.81	542.63	76.59
Price / Cash	0.40	20.07	43.26	56.33
Price / Book	N/A	8.11	9.93	6.97
Net Income	$35.64M	-$3.91M	$3.55B	$333.62M
7 Day Performance	-1.32%	9.43%	1.70%	1.09%
1 Month Performance	7.14%	76.62%	0.49%	3.08%
1 Year Performance	-80.67%	140.55%	39.41%	35.68%

Eagle Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EGRX Eagle Pharmaceuticals	N/A	$0.38 flat	N/A	-80.7%	$4.87M	$257.55M	0.32	100
VTGN VistaGen Therapeutics	2.5509 of 5 stars	$0.60 -3.6%	$0.95 +58.3%	-71.2%	$24.66M	$490K	N/A	40
AEON AEON Biopharma	0.8381 of 5 stars	$0.94 -1.1%	N/A	+60.9%	$24.04M	N/A	5.22	5	News Coverage Upcoming Earnings
TXMD TherapeuticsMD	0.8601 of 5 stars	$2.07 +2.5%	N/A	+36.3%	$23.38M	$3.02M	N/A	420	News Coverage Earnings Report Upcoming Earnings High Trading Volume
AKAN Akanda	0.8035 of 5 stars	$30.00 -27.0%	N/A	-69.5%	$21.95M	$840K	N/A	110	Short Interest Increase Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EGRX) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. VTGN, AEON, TXMD, AKAN, and VYNE

How does Eagle Pharmaceuticals compare to VistaGen Therapeutics?

Summary

How does Eagle Pharmaceuticals compare to AEON Biopharma?

Summary

How does Eagle Pharmaceuticals compare to TherapeuticsMD?

Summary

How does Eagle Pharmaceuticals compare to Akanda?

Summary

How does Eagle Pharmaceuticals compare to VYNE Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Eagle Pharmaceuticals (EGRX) Competitors

EGRX vs. VTGN, AEON, TXMD, AKAN, and VYNE

How does Eagle Pharmaceuticals compare to VistaGen Therapeutics?

Which has more volatility & risk, VTGN or EGRX?

Is VTGN or EGRX more profitable?

Does the media favor VTGN or EGRX?

Do analysts prefer VTGN or EGRX?

Which has stronger valuation & earnings, VTGN or EGRX?

Do institutionals and insiders have more ownership in VTGN or EGRX?

Summary

How does Eagle Pharmaceuticals compare to AEON Biopharma?

Do insiders & institutionals have more ownership in AEON or EGRX?

Which has more risk & volatility, AEON or EGRX?

Does the media favor AEON or EGRX?

Is AEON or EGRX more profitable?

Which has higher valuation and earnings, AEON or EGRX?

Do analysts rate AEON or EGRX?

Summary

How does Eagle Pharmaceuticals compare to TherapeuticsMD?

Do insiders & institutionals have more ownership in TXMD or EGRX?

Which has more risk & volatility, TXMD or EGRX?

Does the media favor TXMD or EGRX?

Is TXMD or EGRX more profitable?

Which has higher valuation and earnings, TXMD or EGRX?

Do analysts rate TXMD or EGRX?

Summary

How does Eagle Pharmaceuticals compare to Akanda?

Which has stronger earnings and valuation, EGRX or AKAN?

Which has more risk and volatility, EGRX or AKAN?

Do analysts rate EGRX or AKAN?

Do institutionals & insiders have more ownership in EGRX or AKAN?

Does the media refer more to EGRX or AKAN?

Is EGRX or AKAN more profitable?

Summary

How does Eagle Pharmaceuticals compare to VYNE Therapeutics?

Which has stronger earnings and valuation, EGRX or VYNE?

Which has more risk and volatility, EGRX or VYNE?

Do analysts rate EGRX or VYNE?

Do institutionals & insiders have more ownership in EGRX or VYNE?

Does the media refer more to EGRX or VYNE?

Is EGRX or VYNE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

EGRX vs. The Competition

Eagle Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools